Jean‐Daniel Lalau

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4

Jean‐Daniel Lalau, Farshad Kajbaf, Youssef Bennis et al. · Diabetes Care · 2018 · 162 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Disappearance of Aluminic Bone Disease in a Long Term Asymptomatic Dialysis Population Restricting Al(OH) ₃ Intake: Emergence of an Idiopathic Adynamic Bone Disease Not Related to Aluminum

P. Morinière, Martine Cohen‐Solal, S. Belbrik et al. · ˜The œNephron journals/Nephron journals · 2008 · 108 citations

Medicine, Nephrology, Bone Metabolism +16

Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.

M Phlipponneau, M Nocaudie, Jacques Epelbaum et al. · The Journal of Clinical Endocrinology & Metabolism · 1994 · 105 citations

Medicine, Endocrinology, Nuclear Medicine +15

Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination.

Jean‐Daniel Lalau, M Andréjak, P Morinière et al. · PubMed · 1989 · 96 citations

Medicine, Nephrology, Pharmacokinetics +17